Literature DB >> 1469012

Treatment of slipped capital femoral epiphysis with a spica cast.

M C Meier1, L C Meyer, R L Ferguson.   

Abstract

Thirteen patients who had seventeen slipped capital femoral epiphyses were managed with a spica cast between 1984 and 1986. The average time in the plaster cast was three months. Complications were noted in fourteen of the hips. Three pressure sores developed in two patients. Further slipping developed in three hips once the cast had been removed, and chondrolysis developed in one of these hips. Chondrolysis developed in eight additional hips, and the lesion was transient in four of them. Degenerative changes developed in all nine hips with chondrolysis, regardless of whether the chondrolysis was transient or permanent. The degenerative changes were Iowa Grade I in three of these hips, Grade II in two hips, and Grade III in four. Chondrolysis developed in six of the eight black patients and in four of the five black boys. Chondrolysis developed in six of the nine hips that had a Grade-II or III slip. These findings have led us to abandon the use of a spica cast as a mode of treatment for slipped capital femoral epiphysis.

Entities:  

Mesh:

Year:  1992        PMID: 1469012

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  3 in total

Review 1.  [Early and late complications and their management in slipped capital femoral epiphysis].

Authors:  F F Fernandez; O Eberhardt; T Wirth
Journal:  Orthopade       Date:  2019-08       Impact factor: 1.087

Review 2.  Evolving Understanding of and Treatment Approaches to Slipped Capital Femoral Epiphysis.

Authors:  James D Wylie; Eduardo N Novais
Journal:  Curr Rev Musculoskelet Med       Date:  2019-06

Review 3.  Treatment of stable slipped capital femoral epiphysis: systematic review and exploratory patient level analysis.

Authors:  H Naseem; S Chatterji; K Tsang; M Hakimi; A Chytas; S Alshryda
Journal:  J Orthop Traumatol       Date:  2017-08-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.